Medicare Part D drugs starting with T
168 drugs start with T; 79 of them are on at least 90% of 2026 Part D formularies. Part D spending was highest for Trulicity in 2024: $5.5 billion, what plans and patients paid at the pharmacy before rebates.
Which drugs start with T?
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Tabloid (thioguanine) | 100% | Tier 5 | $839 thousand |
| Tabrecta (capmatinib) | 100% | Tier 5 | $124 million |
| Tacrolimus | 100% | Tier 4 | $86 million |
| Tadalafil | 100% | Tier 4 | $81 million |
| Tadliq (tadalafil) | 0.7% | Tier 5 | $174 thousand |
| Tafinlar (dabrafenib) | 100% | Tier 5 | $174 million |
| Tafluprost | 1.4% | Tier 4 | $15 million |
| Tagrisso (osimertinib) | 100% | Tier 5 | $1.6 billion |
| Takhzyro (lanadelumab-flyo) | 6.7% | Tier 5 | $223 million |
| Talicia (amoxicillin / omeprazole / rifabutin) | 21.4% | Tier 4 | $3 million |
| Taltz (ixekizumab) | 3.5% | Tier 5 | $698 million |
| Talzenna (talazoparib) | 100% | Tier 5 | $60 million |
| Tamiflu (oseltamivir) | under 0.1% | Tier 1 | $56 thousand |
| Tamoxifen | 100% | Tier 2 | $10 million |
| Tamsulosin hydrochloride | 100% | Tier 1 | $308 million |
| Tanlor (methocarbamol) | 0.5% | Tier 2 | $84 thousand |
| Targretin (bexarotene) | 0.2% | Tier 5 | $5 million |
| Tarina 24 FE (ethinyl estradiol / norethindrone acetate) | 78.5% | Tier 2 | $3 thousand |
| Tarina Fe (ethinyl estradiol / norethindrone acetate) | 94.8% | Tier 2 | no 2024 match |
| Tarpeyo (budesonide) | 1.2% | Tier 5 | $38 million |
| Tascenso (fingolimod) | 1.3% | Tier 5 | $2 million |
| Tasigna (nilotinib) | 4.8% | Tier 5 | $427 million |
| Tasimelteon | 83.3% | Tier 5 | $31 million |
| Tasmar (tolcapone) | under 0.1% | Tier 1 | $129 thousand |
| Tavaborole | 0.8% | Tier 4 | $20 million |
| Tavalisse (fostamatinib) | 4.5% | Tier 5 | $47 million |
| Tavneos (avacopan) | 38.2% | Tier 5 | $76 million |
| Tazarotene | 100% | Tier 4 | $2 million |
| Tazicef (ceftazidime) | 71.4% | Tier 4 | $33 thousand |
| Tazorac (tazarotene) | 3.9% | Tier 4 | $1 million |
| Tazverik (tazemetostat) | 100% | Tier 5 | $25 million |
| Tecfidera (dimethyl fumarate) | 0.3% | Tier 5 | $163 million |
| Teflaro (ceftaroline fosamil) | 85% | Tier 5 | $13 million |
| Tegretol (carbamazepine) | 1.8% | Tier 1 | $27 million |
| Tekturna (aliskiren) | under 0.1% | Tier 1 | $868 thousand |
| Telmisartan | 96.8% | Tier 1 | $38 million |
| Temazepam | 96.9% | Tier 1 | $27 million |
| Tencon (acetaminophen / butalbital) | 2.5% | Tier 1 | $2 thousand |
| Tenivac (Td vaccine) | 100% | Tier 1 | $2 million |
| Tenofovir disoproxil fumarate | 100% | Tier 4 | $14 million |
Show the other 128 drugs
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Tenoretic (atenolol / chlorthalidone) | under 0.1% | Tier 1 | $51 thousand |
| Tenormin (atenolol) | under 0.1% | Tier 1 | $3 million |
| Tepmetko (tepotinib) | 100% | Tier 5 | $41 million |
| Terazosin | 100% | Tier 1 | $29 million |
| Terbinafine | 100% | Tier 1 | $10 million |
| Terbutaline sulfate | 56.5% | Tier 4 | $868 thousand |
| Terconazole | 100% | Tier 2 | $4 million |
| Teriflunomide | 77.9% | Tier 5 | $85 million |
| Teriparatide | 78.8% | Tier 5 | $213 million |
| Testosterone | 99.3% | Tier 4 | $93 million |
| Testosterone cypionate | 99.1% | Tier 2 | $41 million |
| Testosterone enanthate | 100% | Tier 3 | $796 thousand |
| Tetrabenazine | 100% | Tier 4 | $41 million |
| Tetracycline hydrochloride | 83% | Tier 4 | $5 million |
| Texacort (hydrocortisone) | 0.4% | Tier 4 | $53 thousand |
| Thalitone (chlorthalidone) | 0.1% | Tier 4 | $578 thousand |
| Thalomid (thalidomide) | 100% | Tier 5 | $20 million |
| Theo-24 (theophylline) | 14% | Tier 4 | $3 million |
| Theophylline | 100% | Tier 2 | $17 million |
| Thiola (tiopronin) | 2.3% | Tier 5 | $4 million |
| Thioridazine | 100% | Tier 3 | $2 million |
| Thiothixene | 100% | Tier 4 | $2 million |
| Thyquidity (levothyroxine sodium) | under 0.1% | Tier 2 | $257 thousand |
| Tiadylt (diltiazem hydrochloride) | 96.4% | Tier 2 | $6 million |
| Tiagabine hydrochloride | 100% | Tier 4 | $6 million |
| Tiazac (diltiazem hydrochloride) | under 0.1% | Tier 1 | $77 thousand |
| Tibsovo (ivosidenib) | 100% | Tier 5 | $265 million |
| Ticagrelor | 99.9% | Tier 3 | no 2024 match |
| Ticovac (tick-borne encephalitis vaccine) | 100% | Tier 1 | $106 thousand |
| Tigecycline | 100% | Tier 4 | $2 million |
| Tiglutik (riluzole) | 2.1% | Tier 5 | no 2024 match |
| Tikosyn (dofetilide) | 0.2% | Tier 1 | $663 thousand |
| Tilia Fe (ethinyl estradiol / norethindrone acetate) | 85.2% | Tier 2 | $25 thousand |
| Timolol | 100% | Tier 1 | $61 million |
| Timolol hemihydrate | 21.5% | Tier 1 | no 2024 match |
| Timoptic (timolol) | under 0.1% | Tier 1 | no 2024 match |
| Tinidazole | 100% | Tier 2 | $387 thousand |
| Tiopronin | 4.9% | Tier 5 | $906 thousand |
| Tiotropium | 17.1% | Tier 2 | $97 million |
| Tirosint (levothyroxine sodium) | 1% | Tier 4 | $17 million |
| Tivicay (dolutegravir) | 100% | Tier 5 | $629 million |
| Tizanidine | 100% | Tier 2 | $77 million |
| Tobi (tobramycin) | 54.7% | Tier 5 | $46 thousand |
| Tobradex (dexamethasone / tobramycin) | 68.2% | Tier 3 | $16 million |
| Tobramycin | 100% | Tier 1 | $11 million |
| Tobrex (tobramycin) | 9.7% | Tier 4 | $1 million |
| Tolcapone | 6.9% | Tier 5 | $355 thousand |
| Tolmetin | 1.1% | Tier 4 | $3 million |
| Tolterodine tartrate | 98.4% | Tier 2 | $70 million |
| Tolvaptan | 83% | Tier 5 | $28 million |
| Topiramate | 100% | Tier 1 | $69 million |
| Toprol (metoprolol succinate) | under 0.1% | Tier 1 | $5 million |
| Toremifene | 100% | Tier 4 | $871 thousand |
| Torpenz (everolimus) | 76.7% | Tier 5 | no 2024 match |
| Torsemide | 100% | Tier 2 | $55 million |
| Tosymra (sumatriptan) | 0.2% | Tier 4 | $382 thousand |
| Toujeo (insulin glargine) | 89.9% | Tier 3 | $1.1 billion |
| Tovet (clobetasol propionate) | 0.4% | Tier 4 | no 2024 match |
| Toviaz (fesoterodine fumarate) | under 0.1% | Tier 1 | $3 million |
| Tracleer (bosentan) | 2.4% | Tier 5 | $14 million |
| Tradjenta (linagliptin) | 90.5% | Tier 3 | $1.1 billion |
| Tramadol hydrochloride | 99.7% | Tier 2 | $103 million |
| Trandolapril | 96.9% | Tier 1 | $1 million |
| Trandolapril / verapamil hydrochloride | 58.4% | Tier 1 | $2 million |
| Tranexamic acid | 100% | Tier 3 | $3 million |
| Tranylcypromine | 100% | Tier 4 | $3 million |
| Travasol 10 (alanine and 14 more ingredients) | 94% | Tier 4 | no 2024 match |
| Travatan (travoprost) | under 0.1% | Tier 1 | $11 million |
| Travoprost | 90.2% | Tier 4 | $75 million |
| Trazodone hydrochloride | 100% | Tier 1 | $165 million |
| Trelegy (fluticasone furoate / umeclidinium / vilanterol) | 100% | Tier 3 | $5.3 billion |
| Trelstar (triptorelin) | 46% | Tier 4 | $15 million |
| Tremfya (guselkumab) | 91.3% | Tier 5 | $619 million |
| Tresiba (insulin degludec) | 24.3% | Tier 3 | $1.8 billion |
| Tretinoin | 100% | Tier 4 | $22 million |
| Trexall (methotrexate) | 3.3% | Tier 4 | $2 million |
| Tri-Estarylla (ethinyl estradiol / norgestimate) | 96.1% | Tier 2 | $85 thousand |
| Tri-Legest (ethinyl estradiol / norethindrone acetate) | 86.3% | Tier 2 | no 2024 match |
| Tri-Lo- Estarylla (ethinyl estradiol / norgestimate) | 90.8% | Tier 2 | no 2024 match |
| Tri-Lo-Sprintec (ethinyl estradiol / norgestimate) | 93% | Tier 2 | $5 thousand |
| Tri-Mili (ethinyl estradiol / norgestimate) | 89.5% | Tier 2 | $42 thousand |
| Tri-Sprintec (ethinyl estradiol / norgestimate) | 99.1% | Tier 2 | $239 thousand |
| Tri-VyLibra (ethinyl estradiol / norgestimate) | 89.2% | Tier 2 | $1 thousand |
| Tri-VyLibra Lo (ethinyl estradiol / norgestimate) | 84.5% | Tier 2 | $1 thousand |
| Triamcinolone acetonide | 100% | Tier 2 | $68 million |
| Triamterene | 41.2% | Tier 4 | $4 million |
| Triazolam | 18.2% | Tier 4 | $4 million |
| Tribenzor (amlodipine / hydrochlorothiazide / olmesartan medoxomil) | under 0.1% | Tier 1 | $2 million |
| Tridacaine (lidocaine) | 45.5% | Tier 4 | no 2024 match |
| Triderm (triamcinolone acetonide) | 67% | Tier 2 | no 2024 match |
| Trientine hydrochloride | 100% | Tier 5 | $4 million |
| Trifluoperazine | 100% | Tier 3 | $2 million |
| Trifluridine | 100% | Tier 4 | $2 million |
| Trihexyphenidyl hydrochloride | 96.2% | Tier 2 | $3 million |
| Trijardy (empagliflozin / linagliptin / metformin hydrochloride) | 82.4% | Tier 3 | $99 million |
| Trikafta (elexacaftor / ivacaftor / tezacaftor) | 100% | Tier 5 | $725 million |
| Trileptal (oxcarbazepine) | 1.6% | Tier 4 | $19 million |
| Trimethobenzamide hydrochloride | 15.1% | Tier 2 | $93 thousand |
| Trimethoprim | 100% | Tier 2 | $10 million |
| Trimipramine | 100% | Tier 4 | $324 thousand |
| Trintellix (vortioxetine) | 100% | Tier 4 | $392 million |
| Triumeq (abacavir / dolutegravir / lamivudine) | 100% | Tier 4 | $566 million |
| Trophamine 10% (alanine and 21 more ingredients) | 90.5% | Tier 4 | no 2024 match |
| Trospium chloride | 88.7% | Tier 2 | $47 million |
| Trudhesa (dihydroergotamine mesylate) | 0.1% | Tier 5 | $6 million |
| Trulance (plecanatide) | 30.3% | Tier 3 | $123 million |
| Trulicity (dulaglutide) | 95.4% | Tier 3 | $5.5 billion |
| Trumenba (meningococcal B vaccine) | 100% | Tier 1 | $194 thousand |
| Truqap (capivasertib) | 100% | Tier 5 | $184 million |
| Truvada (emtricitabine / tenofovir disoproxil fumarate) | 0.3% | Tier 5 | $4 million |
| Tryngolza (olezarsen) | 5.4% | Tier 5 | no 2024 match |
| Tryptyr (acoltremon) | 0.1% | Tier 4 | no 2024 match |
| Tryvio (aprocitentan) | 0.1% | Tier 4 | no 2024 match |
| Tudorza (aclidinium bromide) | 0.2% | Tier 4 | no 2024 match |
| Tukysa (tucatinib) | 100% | Tier 5 | $139 million |
| Turalio (pexidartinib) | 100% | Tier 5 | $2 million |
| Turqoz (ethinyl estradiol / norgestrel) | 94.2% | Tier 2 | $34 thousand |
| Twinrix (hepatitis A and B vaccine) | 100% | Tier 1 | $38 million |
| Tybost (cobicistat) | 90% | Tier 3 | $270 thousand |
| Tydemy (drospirenone / ethinyl estradiol / levomefolate calcium) | 27% | Tier 2 | no 2024 match |
| Tyenne (tocilizumab-aazg) | 96.9% | Tier 5 | $3 million |
| Tygacil (tigecycline) | under 0.1% | Tier 1 | $243 thousand |
| Tykerb (lapatinib) | under 0.1% | Tier 1 | $3 million |
| Tymlos (abaloparatide) | 55.1% | Tier 5 | $258 million |
| Typhim Vi (typhoid vaccine) | 100% | Tier 1 | $4 million |
| Tyrvaya (varenicline) | 19.2% | Tier 4 | $72 million |
| Tyvaso (treprostinil) | 3.4% | Tier 5 | $737 million |
| Tyzavan (vancomycin) | 13.2% | Tier 4 | no 2024 match |
Source: CMS Part D formulary file, 2026 second quarter; CMS Medicare Part D Spending by Drug, 2024.
What else should you check?
- Every drug, by letterAnd the 20 that cost Medicare most
- Stand-alone drug plans for 2027Premiums and deductibles
- Part D in 2027What changes for drug plans